Drug Profile
Iodixanol - GE Healthcare
Alternative Names: DU 6807; VisipaqueLatest Information Update: 11 Aug 2023
Price :
$50
*
At a glance
- Originator GE Healthcare
- Developer Daiichi Sankyo Company; GE Healthcare
- Class Contrast media; Triiodobenzoic acids
- Mechanism of Action Radiography enhancers; Tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cardiovascular disorders
Most Recent Events
- 11 Aug 2023 First Generic equivalent available in USA used in magnetic resonance imaging (MRI) procedures
- 25 Jun 2019 Daiichi Sankyo agrees to return marketing rights for iodixanol to GE Healthcare in Japan
- 24 Apr 2019 GE Healthcare terminates a phase III trial for Cardiovascular disorders (Diagnosis) in USA, due to low subject recruitment (IV) (NCT00335335)